Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Adjuvant Radiotherapy For Intermediate-risk Early-stage Cervical Cancer Post Radical Hysterectomy: A Systematic Review And Meta-analysis

Adjuvant Radiotherapy for Intermediate-Risk Early-Stage Cervical Cancer Post Radical Hysterectomy: A Systematic Review and Meta-Analysis

Pedro Henrique Costa Matos da Silva1,2, Gabriela Oliveira Gonçalves Molino3, Maírla Marina Ferreira Dias4

  • 1Department of Obstetrics and Gynecology, Federal University of Goiás, Goiânia 74690-900, GO, Brazil.

Journal of Clinical Medicine
|June 13, 2025

Related Experiment Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.1K
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

398

View abstract on PubMed

Summary
This summary is machine-generated.

Adjuvant pelvic radiotherapy does not significantly reduce recurrence risk in early-stage cervical cancer. Tumor size of 4 cm or greater is a significant prognostic factor for recurrence, warranting cautious consideration of adjuvant RT.

Area of Science:

  • Gynecology
  • Oncology
  • Radiotherapy

Background:

  • Early-stage cervical cancer (CC) recurrence risk is linked to tumor size, lymphovascular space invasion (LVSI), and deep stromal invasion (DSI).
  • The benefit of adjuvant pelvic radiotherapy (RT) for intermediate-risk early-stage CC after surgery is debated.

Purpose of the Study:

  • To evaluate the efficacy of adjuvant RT in reducing recurrence in early-stage CC patients with intermediate-risk factors.
  • To identify prognostic factors for recurrence in this patient group.

Main Methods:

  • Systematic literature search of PubMed, Embase, and Cochrane databases.
  • Meta-analysis of nine studies (1504 patients) comparing adjuvant RT versus observation.
  • Outcomes included recurrence, local recurrence, death, 5-year overall survival (5y-OS), and 5-year disease-free survival (5y-DFS).
Keywords:
Sedlis criteriacervical cancerintermediate riskradiotherapy

Related Experiment Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.1K
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

398

Main Results:

  • No statistically significant differences were found in recurrence, local recurrence, death, 5y-OS, or 5y-DFS between adjuvant RT and observation groups.
  • Tumor size (TS) ≥ 4 cm was identified as an independent prognostic risk factor for recurrence (HR 1.83, p=0.02).

Conclusions:

  • Adjuvant RT does not appear to reduce recurrence risk in early-stage cervical cancer patients with intermediate-risk factors.
  • Tumor size ≥ 4 cm is a significant prognostic factor for recurrence.
  • Adjuvant RT use in this population should be approached with caution pending further trial results.
recurrence